SCHEMBL16617740

SCHEMBL16617740

C[C@@H](C#N)NC(=O)[C@@H]1CC(F)(F)CC[C@H]1c1oc(C(F)(F)C(F)(F)F)nc1-c1ccc(C(=O)N2CCOCC2)cc1

nearest known ligand 0.41

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CTSK P43235 3/20 0.41
NR3C1 P04150 11/20 0.38
HDAC4 P56524 1/20 0.37
PGR P06401 8/20 0.37
ELANE P08246 2/20 0.36
CYP2C8 P10632 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
KMT2A Q03164 1/20 0.34
LIPC P11150 1/20 0.34
LIPG Q9Y5X9 1/20 0.34
CTSC P53634 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16617297 0.93 CTSK (0.40) CTSKNR3C1HDAC4PGRELANE
SCHEMBL16626963 0.91 CTSK (0.40) CTSKNR3C1HDAC4PGRELANE
SCHEMBL16626962 0.90 CTSK (0.42) CTSKNR3C1HDAC4PGRELANE
SCHEMBL16617284 0.89 CTSK (0.47) CTSKNR3C1HDAC4PGR
SCHEMBL16618103 0.88 CTSK (0.54) CTSKNR3C1HDAC4PGRCYP2C8
SCHEMBL16637865 0.87 HDAC4 (0.40) CTSKNR3C1HDAC4PGRELANE
SCHEMBL16617516 0.87 HDAC4 (0.40) CTSKNR3C1HDAC4PGRELANE
SCHEMBL16616939 0.87 HDAC4 (0.42) CTSKNR3C1HDAC4PGR
SCHEMBL16617777 0.87 HDAC4 (0.42) CTSKNR3C1HDAC4PGR
SCHEMBL16617800 0.80 CTSK (0.64) CTSKNR3C1HDAC4PGRCYP2C8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9458181-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2016-10-04 US claimed
US-20150099719-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME LLC 2015-04-09 US claimed
US-9458181-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2016-10-04 US disclosed
US-9458181-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2016-10-04 US disclosed
WO-2015054089-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed
US-20150099719-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME LLC 2015-04-09 US disclosed
US-20150099719-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME LLC 2015-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099719-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS CTSB, CTSS, CTSZ CTSK 4/4885NR3C1 4472/4885HDAC4 778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.